-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Judging from the disclosed three-quarter reports of listed companies, over 80% of the A-share listed pharmaceutical companies’ total R&D investment in the first three quarters has increased compared with the same period last year.
Among them, 69 R&D investment has exceeded that of last year, involving medical devices and medical services.
, Chemical pharmacy, traditional Chinese medicine, biological products, medical commerce and other sub-industry companies
.
In terms of the magnitude of change, Guofa shares ranked first with a growth rate of more than one hundred times.
The R&D investment in the first three quarters of this year was as high as 5.
110 million yuan, a year-on-year increase of 22371.
88%
.
The company invested only 50,100 yuan in research and development last year
.
In the 2021 semi-annual report, Guofa stated that the company's R&D expenses are mainly the R&D investment of its subsidiary, Goldman Sachs.
The company acquired Goldman Sachs at the end of last year.
In this period, its income statement was included in the income statement consolidation scope, and R&D expenses have changed significantly year-on-year.
.
It is worth mentioning that since its listing in 2003, the operating income of the State Development Corporation has not improved, and the total net profit for the 18 years of listing has been about 480 million yuan
.
The company’s 2021 third quarter results announcement showed that the company achieved operating income of approximately 305 million yuan in the first three quarters, a year-on-year increase of 67.
99%; net profit attributable to shareholders of listed companies was 7,804,300 yuan, a year-on-year increase of 247.
20%
.
Yixintang’s R&D investment in the first three quarters of this year was 3,866,500 yuan, and the company’s R&D investment for the whole year of last year was 839,500 yuan, which has doubled
.
It is understood that since 2020, the increase in pharmacy O2O platform orders and the significant increase in the proportion of sales have made more and more pharmacy managers aware of the importance of O2O business, but O2O business requires a large amount of investment in the early stage in order to expand O2O Since 2020, Yixintang has increased its investment in research and development, and improved its professional capabilities and O2O service capabilities
.
Guangzheng Ophthalmology has invested 1,931,800 yuan in research and development in the first three quarters.
Last year, the investment amount was nearly 542,400 yuan
.
Public information shows that the company is a professional ophthalmology chain medical enterprise, focusing on the ophthalmic medical service market in large and medium-sized cities, and is mainly engaged in the investment and management of ophthalmic hospitals..
At present, 13 professional eye hospitals have been opened in 10 central cities including Shanghai, Chengdu, Chongqing, Zhengzhou, Nanchang, Hohhot, Jinan, Qingdao, Wuxi, Yiwu, etc.
, forming a mature platform hospital replication chain development model and supporting management system
.
Sharpais is a pharmaceutical manufacturing company whose main business is the production, research and development and sales of chemical preparations and Chinese patent medicines
.
In the first three quarters of 2021, the company's R&D investment amounted to 80.
225 million yuan.
Last year, the investment for the whole year was 27.
809 million yuan, nearly quadrupling
.
At the same time, the company's net profit attributable to shareholders of listed companies in the first three quarters of this year was 36.
147 million yuan, turning losses into profits year-on-year
.
In addition, Dongfang Biotechnology invested 243 million yuan in the first nine months of this year, which doubled the total of 93,749,500 yuan last year, mainly because the company increased its R&D-related investment
.
The company's performance in the first three quarters still increased significantly
.
For the next development, the company said it will focus on POCT (point-of-care) rapid diagnosis of the entire industry chain, and focus on the development of molecular diagnostics and liquid biochips two major industries
.
From the perspective of the industry, pharmaceutical companies have obviously paid more attention to R&D investment, which also shows that the past “light R&D and focus on sales” model is changing
.
And behind the increase of R&D investment by pharmaceutical companies is closely related to the pharmaceutical policy environment such as centralized procurement.
As centralized procurement forces pharmaceutical companies to innovate, the profits of generic drugs are squeezed, and companies have to find new ways to make profits
.
However, the industry also reminds that you cannot blindly chase innovative pharmaceutical companies.
On the one hand, these companies have high valuations and on the other hand, there is a high risk of R&D failure.
We must pay attention to the commercialization prospects and market demand of new products, and treat new drugs rationally.
There is room for improvement in the valuation of companies
.
Among them, 69 R&D investment has exceeded that of last year, involving medical devices and medical services.
, Chemical pharmacy, traditional Chinese medicine, biological products, medical commerce and other sub-industry companies
.
In terms of the magnitude of change, Guofa shares ranked first with a growth rate of more than one hundred times.
The R&D investment in the first three quarters of this year was as high as 5.
110 million yuan, a year-on-year increase of 22371.
88%
.
The company invested only 50,100 yuan in research and development last year
.
In the 2021 semi-annual report, Guofa stated that the company's R&D expenses are mainly the R&D investment of its subsidiary, Goldman Sachs.
The company acquired Goldman Sachs at the end of last year.
In this period, its income statement was included in the income statement consolidation scope, and R&D expenses have changed significantly year-on-year.
.
It is worth mentioning that since its listing in 2003, the operating income of the State Development Corporation has not improved, and the total net profit for the 18 years of listing has been about 480 million yuan
.
The company’s 2021 third quarter results announcement showed that the company achieved operating income of approximately 305 million yuan in the first three quarters, a year-on-year increase of 67.
99%; net profit attributable to shareholders of listed companies was 7,804,300 yuan, a year-on-year increase of 247.
20%
.
Yixintang’s R&D investment in the first three quarters of this year was 3,866,500 yuan, and the company’s R&D investment for the whole year of last year was 839,500 yuan, which has doubled
.
It is understood that since 2020, the increase in pharmacy O2O platform orders and the significant increase in the proportion of sales have made more and more pharmacy managers aware of the importance of O2O business, but O2O business requires a large amount of investment in the early stage in order to expand O2O Since 2020, Yixintang has increased its investment in research and development, and improved its professional capabilities and O2O service capabilities
.
Guangzheng Ophthalmology has invested 1,931,800 yuan in research and development in the first three quarters.
Last year, the investment amount was nearly 542,400 yuan
.
Public information shows that the company is a professional ophthalmology chain medical enterprise, focusing on the ophthalmic medical service market in large and medium-sized cities, and is mainly engaged in the investment and management of ophthalmic hospitals..
At present, 13 professional eye hospitals have been opened in 10 central cities including Shanghai, Chengdu, Chongqing, Zhengzhou, Nanchang, Hohhot, Jinan, Qingdao, Wuxi, Yiwu, etc.
, forming a mature platform hospital replication chain development model and supporting management system
.
Sharpais is a pharmaceutical manufacturing company whose main business is the production, research and development and sales of chemical preparations and Chinese patent medicines
.
In the first three quarters of 2021, the company's R&D investment amounted to 80.
225 million yuan.
Last year, the investment for the whole year was 27.
809 million yuan, nearly quadrupling
.
At the same time, the company's net profit attributable to shareholders of listed companies in the first three quarters of this year was 36.
147 million yuan, turning losses into profits year-on-year
.
In addition, Dongfang Biotechnology invested 243 million yuan in the first nine months of this year, which doubled the total of 93,749,500 yuan last year, mainly because the company increased its R&D-related investment
.
The company's performance in the first three quarters still increased significantly
.
For the next development, the company said it will focus on POCT (point-of-care) rapid diagnosis of the entire industry chain, and focus on the development of molecular diagnostics and liquid biochips two major industries
.
From the perspective of the industry, pharmaceutical companies have obviously paid more attention to R&D investment, which also shows that the past “light R&D and focus on sales” model is changing
.
And behind the increase of R&D investment by pharmaceutical companies is closely related to the pharmaceutical policy environment such as centralized procurement.
As centralized procurement forces pharmaceutical companies to innovate, the profits of generic drugs are squeezed, and companies have to find new ways to make profits
.
However, the industry also reminds that you cannot blindly chase innovative pharmaceutical companies.
On the one hand, these companies have high valuations and on the other hand, there is a high risk of R&D failure.
We must pay attention to the commercialization prospects and market demand of new products, and treat new drugs rationally.
There is room for improvement in the valuation of companies
.
